MG
MGRX.US Mangoceuticals, Inc. Common Stock
- Market cap
- USD 3.56M
- P/E
- -
- P/B
- 0.28x
- ROE
- -75.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MGRX.US undervalued?
Graham numberThe Graham number of Mangoceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mangoceuticals, Inc. Common Stock fundamental analysis
No fundamental analysis for Mangoceuticals, Inc. Common Stock yet.
Mangoceuticals, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a …
Full company profileMangoceuticals, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mangoceuticals, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 8.94K | 731K | 616K | 456K | 273K |
| Gross Profit | - | 4.85K | 432K | 380K | 250K | 146K |
| Operating Income | -17.5K | -1.99M | -9.22M | -7.97M | -19.2M | -8.32M |
| EBITDA | -17.5K | -1.99M | -8.09M | -7.96M | -18.8M | -7.79M |
| Net Income | -17.7K | -2.00M | -9.21M | -8.71M | -20.6M | -9.43M |
| EPS | -0.02 | -1.73 | -6.45 | -4.40 | -2.05 | -0.55 |
| Balance Sheet | ||||||
| Total Assets | 22.6K | 1.00M | 1.05M | 15.4M | 16.1M | 14.2M |
| Total Liabilities | 39.3K | 389K | 276K | 1.43M | 891K | 1.65M |
| Shareholders' Equity | -16.7K | 614K | 775K | 13.9M | 15.2M | 12.5M |
| Cash & Short-term Investments | 22.6K | 683K | 739K | 58.7K | 1.49M | 229K |
| Total Debt | 39.3K | 353K | 129K | 215K | 308K | 324K |
| Cash Flow | ||||||
| Operating Cash Flow | -17.5K | -1.35M | -7.00M | -4.86M | -5.85M | -3.14M |
| Capital Expenditure | 43.1K | 43.1K | 3.52K | 0.00 | 5.00 | 8.00 |
| Free Cash Flow | -17.5K | -1.39M | -7.00M | -4.86M | -5.85M | -3.14M |
| Ratios | ||||||
| ROE | - | -325.4% | -1,189.1% | -62.4% | -135.8% | -75.3% |
| ROA | -78.5% | -199.2% | -876.7% | -56.6% | -128.3% | -66.5% |
| Net Profit Margin | - | -22,352.1% | -1,259.4% | -1,413.6% | -4,526.9% | -3,451.7% |
| Debt to Equity | - | 0.57x | 0.17x | 0.02x | 0.02x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mangoceuticals, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 802K | 0.41 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Oct 16, 2024.
Who owns Mangoceuticals, Inc. Common Stock
- Insiders 17.61%
- Institutions 9.01%
- Public & others 73.38%
- Shares outstanding 22.2M
- Free float 15.6M
Top funds holding MGRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 587K | 2.64% | +1,222.14% | Aug 2026 |
| Fidelity Extended Market Index | 76.1K | 0.34% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 14.4K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 13.2K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding MGRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 339K | 1.53% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 186K | 0.84% | +1,317.26% | Jun 2026 |
| Geode Capital Management, LLC | 156K | 0.70% | -19.66% | Jun 2026 |
| Ikarian Capital, LLC | 138K | 0.62% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 123K | 0.55% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 57.2K | 0.26% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 38.4K | 0.17% | 0.00% | Jun 2026 |
| Northern Trust Corp | 37.6K | 0.17% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 36.0K | 0.16% | 0.00% | Jun 2026 |
| Ackerman Capital Advisors, LLC | 34.5K | 0.16% | 0.00% | Jun 2026 |
| ACT Advisors, LLC | 12.3K | 0.06% | -54.16% | Sep 2026 |
| The Goldman Sachs Group Inc | 11.6K | 0.05% | -1.43% | Jun 2026 |
| Csenge Advisory Group, LLC | 10.0K | 0.05% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 6.67K | 0.03% | 0.00% | Jun 2026 |
| Fortitude Family Office LLC | 1.34K | 0.01% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 783.00 | 0.00% | -0.25% | Jun 2026 |
| Barclays PLC | 5.00 | 0.00% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| StoneX Group Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Mangoceuticals, Inc. Common Stock company profile
- Company name
- Mangoceuticals, Inc. Common Stock
- Ticker
- MGRX.US
- Exchange
- USA Stocks
- Listed since
- Mar 21, 2023
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3
- Fiscal year end
- December
- Address
- 17130 N. Dallas Parkway, Dallas, TX, United States, 75248
- Phone
- 214 242 9619
- Website
- mangoceuticals.com
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Mangoceuticals, Inc. Common Stock management
2- Mr. Jacob D. CohenCo-Founder, CEO & Chairman · born 1979
- Mr. Eugene M. JohnstonChief Financial Officer · born 1964